Cyclerion Therapeutics 주식 (NASDAQ: CYCN)

에 대한 최신 뉴스 Cyclerion Therapeutics (NASDAQ:CYCN) 주식

Cyclerion Therapeutics

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics Inc

<a href="https://x.com/RJScaringe/status/1885426301437460517" title="https://x.com/RJScaringe/status/1885426301437460517">https://x.com/RJScaringe/status/1885426301437460517</a>

News

RIVN

Rivian Automotive Founder And CEO RJ Scaringe Posts On X "R2 expansion moving quickly!"

Wall Street analysts rerated Atlassian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) and raised their price targets on the stock after its <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43355332/atlassian-q2-earnings-revenue-beat-eps-beat-strong-guidance-infusing-ai-and-more" rel="noreferrer noopener">upbeat quarterly print</a> Thursday.
<ul>
<li>JMP Securities analyst Patrick Walravens reiterated Atlassian with a <a href="https://www.benzinga.com/quote/TEAM/analyst-ratings" target="_blank" rel="noreferrer noopener">Market Perform</a>.</li>
<li>Raymond James analyst Adam Tindle maintained Atlassian with an Outperform and raised the price target from&nbsp;$250&nbsp;to&nbsp;$330.</li>
<li>Truist Securities analyst Joel Fishbein reiterated Atlassian with a Buy and raised the price target from&nbsp;$300&nbsp;to&nbsp;$350.</li>
<li>Keybanc analyst Jason Celino maintained Atlassian with an Overweight and raised the price target from&nbsp;$315&nbsp;to&nbsp;$365.</li>
<li>Cantor Fitzgerald analyst Thomas Blakey reiterated Atlassian with a Neutral and raised the price target from&nbsp;$264&nbsp;to&nbsp;$304.</li>
<li>Scotiabank analyst Nick Altmann maintained Atlassian with a Sector Perform and raised the price target from $250 to $330.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43315306/strykers-strategic-moves-impress-analysts-spine-implant-sale-and-nari-deal-set-to-drive-future-growth" target="_blank" rel="noreferrer noopener">Stryker&#8217;s Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth</a>
JMP Securities: Walravens rerated Atlassian after it reported better-than-expected fiscal second-quarter 2025 results. The company posted adjusted EPS of $0.96 (consensus $0.76) on total revenue of $1.286 billion (consensus $1.240 billion), reflecting 21% year-over-year growth, flat with last quarter.
Cloud revenue reached $847 million, up 30% year-over-year, well ahead of guidance of 25.5%. This marked a slight decline from 31% last quarter but exceeded the consensus estimate of 26%.
Data Center revenue totaled $362 million, increasing 32% year-over-year, down from 38% last quarter but surpassing the consensus of 28%.
Billings came in ahead of expectations at $1.470 billion (consensus $1.378 billion), representing 21% year-over-year growth.
Walravens projected third-quarter revenue of $1.35 billion and EPS of 88 cents.
Raymond James: Tindle rerated after Atlassian&#8217;s quarterly results that featured a continuation of elite Cloud growth at scale, and guidance above the analyst&#8217;s buy-side bogeys suggests durability. 
The analyst&#8217;s recent upgrade was predicated on a combination of macro indicators with a detailed NRR build that suggested Cloud growth could ultimately end closer to mid/high 20% than the initial low-20% guidance, which is materializing. 
An incremental focus on Enterprise customers provides both risk and opportunity as mid-market-focused tech companies attempting to grow in Enterprise can ultimately destroy unit economics and incremental capital investment. Tindle intends to monitor material changes in contribution margin but noted that initial customer acquisition tends to be costly. 
Atlassian has landed 85% of the Fortune 500, and this $14 billion opportunity unfolds alongside a new CRO with roots at SAP.
In the longer term, the AI opportunity Tindle spotlighted through sensitivity analysis on Rovo is gaining momentum, with 1 million+ monthly active users of Rovo and Atlassian Intelligence features. The analyst&#8217;s prior concern with Atlassian&#8217;s AI strategy was that it drove up customer acquisition cost (CAC) with an indeterminate impact on long-term value (LTV), meaning incremental customer economics were worsening. However, gross margin has continued to outperform, and Atlassian is showing incremental operating leverage during this ramp-up period.
The introduction of paid SKUs for AI has become an increased focus and a positive step toward the monetization of AI, which could be very meaningful over time with proper execution. This also has potential positive impacts on Atlassian&#8217;s valuation multiple, and Tindle noted little reason to make a valuation call here based on the longer-term potential.
Tindle projected third-quarter revenue of $1.35 billion and EPS of 92 cents.
Truist Securities: Atlassian&#8217;s second-quarter 2025 release delivered a substantial upside to Fishbein&#8217;s top and bottom line estimates. Atlassian called out stability in the SMB segments that had challenged the business in prior years, as well as traction with their enterprise sales motion and new product offerings. Fishbein noted that the company has established a solid foundation, and more can go right to drive upside to expectations through the year.
Fishbein projected third-quarter revenue of $1.35 billion and EPS of 90 cents.
Keybanc: Atlassian reported another strong quarter of Cloud and DC outperformance, driven by continued stabilization in SMB and paid seat expansions, solid enterprise execution, and migration activity. Significantly, the magnitude of the 2025 Cloud guidance raise to 26.5% (250 bps raise) was most impressive. 
Given the upcoming release of certain blockers (such as FedRAMP), the narrowing of feature/price gaps between DC and Cloud, and the improvement of enterprise motion, Celino noted that the momentum for Cloud is just getting started.
Celino projected third-quarter revenue of $1.35 billion and EPS of 91 cents.
Cantor Fitzgerald: Blakey&#8217;s rerating followed a solid fiscal second-quarter 2025 report and fiscal third-quarter outlook driven by strong Enterprise, AI, and pricing. Cloud revenue was partially driven by better-than-expected seat expansion and migrations, and seat expansion has also stabilized in SMB. 
The company reiterated its prudent posture on guidance, and Blakey noted that third-quarter 2025 Q/Q growth appears to be increasingly conservative. In addition to macro as a reason for conservatism, new CRO (January 2025) and strong &#8216;mega deals&#8217; in the fiscal second quarter could be additional reasoning around the fiscal third-quarter top-line guide.
Blakey projected third-quarter revenue of $1.35 billion and EPS of 91 cents.
Scotiabank: After a choppy start to software earnings season, Atlassian&#8217;s strong results stand out and likely provide investors with some comfort around software end market dynamics. Atlassian continues to post more significant upside to Cloud, though its prudent approach to guidance continues. 
Macro-wise, the company noted the environment was stable Q/Q, though seat expansion and migration activity exceeded expectations. Atlassian posted its best quarter of $1 million ACV deals and noted 1 million MAUs for its AI features and products. 
Ultimately, two clean quarters of Cloud upside and management leaving room for further upside in the second half should help the shares continue to work. Altmann is getting increasingly comfortable with the story and found the 40% Y/Y growth in Premium &amp; Enterprise and heightened Cloud adoption driven by Atlassian&#8217;s new AI capabilities, perhaps the most underappreciated aspect of the print.
Altmann projected third-quarter revenue of $1.35 billion.
Price Action: TEAM stock is up 13.1% at $310.95 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43314549/f5-sees-big-wins-in-multi-cloud-ai-security-and-it-refresh-analysts-forecast-more-upside" target="_blank" rel="noreferrer noopener">F5 Sees Big Wins in Multi-Cloud, AI Security, and IT Refresh, Analysts Forecast More Upside</a></li>
</ul>
Photo: Shutterstock

Price Target

Reiteration

Analyst Ratings

Trading Ideas

TEAM

Atlassian's Cloud Strength, AI Momentum, Enterprise Deals Impress Analysts

Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) has outperformed the market over the past 15 years by 1.96% on an annualized basis producing an average annual return of 14.25%. Currently, Encompass Health has a market capitalization of $9.91 billion. 
Buying $100 In EHC: If an investor had bought $100 of EHC stock 15 years ago, it would be worth $727.37 today based on a price of $98.41 for EHC at the time of writing.
<h3>Encompass Health's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738355711_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Encompass Health 15 Years Ago Would Be Worth This Much Today

Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program <a target="_blank" href="https://www.benzinga.com/25/01/43294006/trump-white-house-blames-outage-for-medicaid-website-lockout-we-have-confirmed-no-payments-have-been-affected" rel="noreferrer noopener">are key focus areas for potential healthcare reforms.</a>
Goldman Sachs analyst Salveen Richter, however, warns that federal Medicaid cuts could lead to stricter policies and lower drug coverage.
Per Richter, the 340B program is currently facing increased scrutiny, with proposed reforms that could potentially benefit biopharma companies by limiting eligibility for drug discounts, which would enable &#8220;transfer of profits&#8221; from providers back to biopharma.
This shift could positively impact major biopharma companies with high exposure to 340B drugs, such as Merck &amp; Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) and Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>).
However, the specifics of these reforms are still uncertain, which could cause &#8220;volatility&#8221; in the healthcare sector until more details are released.
At the same time, Medicaid funding and eligibility changes are under consideration as potential cost-saving measures by the new administration.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43392796/abbvie-jumps-after-q4-earnings-beat-skyrizi-and-rinvoq-boom-offsets-humira-decline" rel="noreferrer noopener">AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline</a>
These changes could have negative effects on biopharma companies with significant Medicaid drug exposure, including AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Gilead Sciences, and Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), whose top Medicaid drugs make up a large percentage of their US sales.
Overall, for the 340B program, the analyst sees potential policy/legal outcomes that would move dynamics towards a transfer of profits from providers to biopharma companies as a positive for much of the biopharma sector.
Meanwhile, potential Medicaid changes could create &#8220;potential headwinds&#8221; for healthcare providers and biopharma companies, though the exact effects remain uncertain.
The healthcare industry is awaiting further clarity on these proposed policy changes and their implications.
Overall, the analyst notes that exposure to Medicaid and 340B can vary widely by product and indication.
The top three highest-spend drugs for Medicaid (as of 2022) are AbbVie&#8217;s Humira, Gilead&#8217;s Biktarvy and Eli Lilly&#8217;s Trulicity for type 2 diabetes and cardiovascular disease.
For these drugs, Medicaid and 340B spending represented ~15-30% of the drugs' FY22 and FY23 revenue.
Further, 340B impact may vary for different methods of administration within the same indication &#8211; for example, Gilead&#8217;s expects lower 340B exposure for injectables for PrEP than for daily orals &#8211; and expansion of eligibility for 340B discounts may have an outsized impact on certain therapeutics over others.
Overall, 340B reform would serve as a tailwind to biopharma, as the aforementioned initiatives are generally intended to limit access to the statutory discount.
On the other hand, spending cuts to Medicaid could have a negative impact to volume if they have the effect of reducing coverage, the analyst writes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43308041/chevron-ge-vernova-engine-no-1-bet-big-on-ai-power-but-is-it-too-late" target="_blank" rel="noreferrer noopener">Chevron, GE Vernova Bet Big On AI Power: Data Centers To Consume Enough Natural Gas To Power 3.5 Million Homes</a></li>
</ul>

Equities

Markets

Movers

General

ABBV

GILD

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts

Lemonade's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) short percent of float has risen 19.89% since its last report. The company recently reported that it has 16.85 million shares sold short, which is 32.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lemonade Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738355422_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lemonade has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lemonade's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lemonade's peer group average for short interest as a percentage of float is 4.61%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

LMND

(LMND) - Analyzing Lemonade's Short Interest

Quantum-Si's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NYSE">QSI</a>) short percent of float has fallen 21.41% since its last report. The company recently reported that it has 18.59 million shares sold short, which is 18.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Quantum-Si Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738355417_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Quantum-Si has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Quantum-Si's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Quantum-Si's peer group average for short interest as a percentage of float is 6.13%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(QSI) - Analyzing Quantum-Si's Short Interest

Once upon a time, earning six figures was a badge of honor – a golden ticket that signified you'd made it into the upper class. But now? Not so much. Turns out, nearly a quarter of American workers – 21.1% or over 38 million people – earned at least $100,000 last year, according to DQYDJ.com.
That's a jaw-dropping number when you consider what six figures used to represent. But today, $100K isn't the luxury salary it once was. In fact, for many people, it's the bare minimum they believe they need to stop worrying about money altogether.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich-2">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
$100K: The New Baseline for Feeling "Okay"
Everything is more expensive now. So it's no surprise that a report from Edelman Financial Engines found 58% of Americans think earning $100K a year is necessary just to avoid worrying about everyday living expenses. For a quarter of respondents, even six figures doesn't cut it – they say at least $200K is needed to feel comfortable.
And they're not wrong. Inflation, skyrocketing home prices and rising interest rates have pushed living costs to extremes. What used to be a "dream salary" is now the starting point for many just to make ends meet – never mind saving for retirement, paying down debt or splurging on a vacation.
Trending: <a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a>&nbsp;
The Pressure Is Mounting
2024 has been another tough financial year for Americans, with inflation hammering household budgets and interest rates leaving <a href="https://www.benzinga.com/real-estate/24/11/41685300/1-in-13-homeowners-are-risking-it-all-heres-why-experts-call-it-a-huge-mistake">homeowners stuck in place</a>. It's no wonder money continues to be a top source of stress for families nationwide. And even with a six-figure salary, many workers are finding it hard to keep up:
• Housing costs are consuming larger chunks of paychecks than ever, with the median home price in the U.S. reaching $416,800 as of late 2024.
• Health care and child care<a href="https://www.benzinga.com/personal-finance/24/07/39778022/dave-ramsey-tells-man-and-wife-spending-80-000-a-year-in-child-care-costs-that-they-have-lost-th"> costs are skyrocketing</a>, putting even more pressure on families with young kids.
• The average American carries over $5,700 in credit card debt and interest rates punish anyone trying to pay it down.
When you add it all up, it's no wonder six figures barely feel enough to breathe.
Trending: Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.
Why It Doesn't Feel Like "Making It"
The truth is, six figures don't go as far as it used to and the data proves it. Here's why:
1. Inflation is Outpacing Wages
While $100K might look good on paper, it's worth <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42917321/consumer-inflation-worries-highest-since-2008-u-of-m-survey-says-wall-street-tumbles-to-2-month-lows">significantly less</a> than a decade ago. Prices on essentials like food, gas and housing have all surged, making it harder to stretch your paycheck.
2. Lifestyle Creep
<a href="https://www.benzinga.com/personal-finance/24/05/38945724/suze-orman-says-stop-wasting-your-money-on-things-designed-to-make-your-life-easier-warns-conven">Earning more often means spending more</a>, whether it's on a bigger home, better schools or just keeping up with rising living costs. That "extra" income disappears quickly.
3. Savings and Retirement Goals Are Higher
Americans now believe they need $1.46 million saved to retire comfortably, according to Northwestern Mutual – a 15% increase from the previous year. Even a six-figure salary doesn't leave enough room to hit those targets for many.
4. The Social Security Question
Younger generations are bracing for cuts to Social Security benefits by 2035, meaning they'll have to rely even more on personal savings – yet another stressor for the $100K crowd.
See Also: The average 401(k) balance soars to a record-breaking high – <a href="https://www.benzinga.com/money/average-401k-balances-soars-to-record-high">Here's how to know if your nest egg is keeping pace.</a>
The Bigger Picture
So, what's the takeaway? A six-figure salary might still sound impressive, but it's become the new baseline for millions of Americans. If you're in that group of workers making at least $100K a year, you might find it's just enough to tread water financially – not thrive.
If you want to make your dollar go further, now's the time to get strategic. <a href="https://www.benzinga.com/money/are-you-rich">Consulting a financial advisor</a> can help you create a plan to stretch your income, invest wisely and prioritize your goals. Whether building wealth, saving for retirement or tackling debt, having a clear road map can make all the difference in making six figures feel more than just the bare minimum.
Read Next:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li><a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a></li>
</ul>

Personal Finance

58% Of People Say $100,000 A Year Is The Bare Minimum To Avoid The Financial Stress Of Daily Life – Here's How Many Actually Earn This

Sprouts Farmers Market's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NYSE">SFM</a>) short percent of float has risen 5.42% since its last report. The company recently reported that it has 6.61 million shares sold short, which is 10.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.99 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sprouts Farmers Market Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738355412_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sprouts Farmers Market has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Sprouts Farmers Market's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sprouts Farmers Market's peer group average for short interest as a percentage of float is 7.78%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(SFM) - Analyzing Sprouts Farmers Market's Short Interest

Goldman Sachs analyst Neil Mehta downgraded Magnolia Oil &amp; Gas Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) and Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>), while reinstating coverage on Expand Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>).
MGY: The analyst downgraded the company from Buy to Neutral and cut <a target="_blank" href="https://www.benzinga.com/quote/mgy/analyst-ratings" rel="noreferrer noopener">the price forecast from $27 to $26</a>.
Mehta writes that the bearish outlook reflects the company&#8217;s outperformance relative to peers.
This performance has been driven by effective cost improvement initiatives and a focus on capital efficiencies in 2024, along with its relatively low leverage, adds the analyst.
While he still anticipates strong operational execution, he believes the stock now reflects these advantages.
The analyst estimates MGY to maintain relatively flat production costs over the next two years as the majority of significant operational cost savings were realized through the company&#8217;s early 2024 cost-saving initiative.
OXY: Mehta downgraded the company from Neutral to Sell and cut <a href="https://www.benzinga.com/quote/oxy/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast from $54 to $45</a>.
The bearish outlook reflects the company's pause on capital returns to shareholders until meaningful balance sheet improvements are achieved. Additionally, while asset sales could support deleveraging, further clarity is needed on their scope and impact, adds the analyst.
Given the less attractive risk/reward profile, with an 8% downside compared to 25% upside for oil-focused peers, the analyst sees limited upside potential.
The analyst increased the estimated FCF yield from 10.0% to 11.0%, citing investors&#8217; growing emphasis on capital returns and the company&#8217;s higher leverage.
EXE: Mehta resumed coverage on the company with a Buy rating and price forecast of $121, <a target="_blank" href="https://www.benzinga.com/quote/exe/analyst-ratings" rel="noreferrer noopener">implying an 18% upside from current levels</a>.
The decision follows the merger of Chesapeake Energy (CHK) <a target="_blank" href="https://www.benzinga.com//node/41070109" rel="noreferrer noopener">and </a><a target="_blank" href="https://www.benzinga.com//node/41070109" rel="noreferrer noopener">Southwestern Energy (SWN)</a>.
The analyst writes that Expand Energy&#8217;s emphasis on capital efficiency, disciplined activity, and risk management strengthens confidence in its operational outlook.
While gas production growth from Haynesville is expected to support rising LNG export demand, the company&#8217;s dual-basin presence in Appalachia and Haynesville provides a low-cost core business in Appalachia with expansion potential in Haynesville, reducing basin takeaway constraints, adds the analyst.
Additionally, its flexible operational strategy offers strong long-term exposure to structural improvements in natural gas prices, says the analyst.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43382627" target="_blank" rel="noreferrer noopener">Chevron Q4 Earnings: Profits Decline Amid Lower Oil Output, Dividend Hike Offers Silver Lining</a></li>
</ul>
Photo: Shutterstock

Large Cap

Downgrades

Goldman Sachs Forecasts Limited Upside For Occidental & Magnolia: What's Next?

WIIM

ONON

Shares of footwear stocks are trading lower in sympathy with Deckers, which fell after Q3 earnings.

Celestica shares are trading higher following better-than-expected Q4 financial results and Q1 guidance issued above estimates.

Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) shares are trading <a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener">marginally higher on Friday.</a>
Yesterday, the company&nbsp;reported quarterly earnings of&nbsp;$2.75&nbsp;per share, which beat the <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43355517/visa-shares-rise-on-solid-q1-results-details" rel="noreferrer noopener">analyst consensus estimate of&nbsp;$2.66</a>.&nbsp;Quarterly revenue came in at $9.51 billion,&nbsp;which beat the analyst consensus estimate of&nbsp;$9.34 billion.
Total cross-border volume on a constant dollar basis increased by 16% in the quarter.
Here are the <a target="_blank" href="https://www.benzinga.com/quote/V/analyst-ratings" rel="noreferrer noopener">analysts&#8217; take on the stock:</a>
<ul>
<li>BofA Securities analyst Jason Kupferberg reiterated the Neutral rating on the stock, raising the price forecast to $363 from $331.</li>
<li>RBC Capital Markets analyst Daniel R. Perlin reiterated the Outperform rating on the stock, raising the price forecast to $395 from $322.</li>
<li>Goldman Sachs analyst Will Nance maintained the Buy rating on Visa, raising the price forecast to $384 from $346.</li>
<li>Oppenheimer analyst Rayna Kumar reiterated the Outperform rating on Visa, raising the price forecast to $390 from $375.</li>
<li>Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani reiterated the Outperform rating on the stock, with a price forecast of $400 from $360.</li>
</ul>
BofA Securities: The analyst notes that the company&#8217;s EPS growth guidance is driven by the first quarter upside and an updated 2025 tax rate assumption.&nbsp;Despite Visa&#8217;s strong business model, the analyst maintains a Neutral rating due to concerns over top-line growth, potential litigation/regulatory risks.
RBC Capital Markets: The analyst attributes the strong quarter to solid holiday spending, elevated FX volatility, and strong cross-border travel.
This, along with increased FY25 net revenue and adjusted EPS guidance, sets a positive backdrop for Visa heading into its February 20th Investor Day.
Goldman Sachs: The analyst projects Visa&#8217;s strong first quarter results to support the stock, citing accelerated volumes, raised guidance, and upbeat consumer outlook.
Despite the strong performance, a tempered share price reaction is anticipated. The analyst expects to focus on Visa&#8217;s VAS strategy and the upcoming Investor Day.
The analyst remains optimistic on Visa and the payments sector, citing stabilized post-COVID spending patterns and easing headwinds.
Oppenheimer: Per the analyst, Visa is well-positioned to capture market share from the ongoing shift from paper-based payments to cards, driving high-single-digit volume growth over the next three years.
Kumar highlights that Visa is a &#8220;top 2025&#8221; idea.
Keefe, Bruyette &amp; Woods: The analyst highlights Visa&#8217;s strong quarter with ongoing volume acceleration, especially in discretionary spend categories, and notes potential upside as the year progresses, with improved constant currency outlook beyond second quarter not fully reflected in guidance.
The analyst notes Visa&#8217;s improved constant currency outlook but cautions that FX headwinds may limit upside.
A lower tax rate boosts 2025 EPS, with potential for further upside if strong volume trends continue beyond the second quarter.
Price Action: V shares are trading higher by 0.36% to $344.30 at last check Friday.
Image from Shutterstock.

Analyst Color

Visa's Q1 Is A Positive Teaser Ahead Of Investor Day: Analyst

INTC

Intel shares are trading lower following soft Q1 guidance.

Southwest Airlines's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) short percent of float has fallen 9.63% since its last report. The company recently reported that it has 31.95 million shares sold short, which is 6.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.96 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Southwest Airlines Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738354523_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Southwest Airlines has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Southwest Airlines's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Southwest Airlines's peer group average for short interest as a percentage of float is 8.46%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Southwest Airlines's Recent Short Interest

Taylor Morrison Home's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMHC#NYSE">TMHC</a>) short percent of float has risen 3.47% since its last report. The company recently reported that it has 2.18 million shares sold short, which is 2.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.58 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Taylor Morrison Home Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738354518_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Taylor Morrison Home has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Taylor Morrison Home's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Taylor Morrison Home's peer group average for short interest as a percentage of float is 10.34%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TMHC

How Is The Market Feeling About Taylor Morrison Home?

Interactive Brokers Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NYSE">IBKR</a>) short percent of float has risen 10.19% since its last report. The company recently reported that it has 1.82 million shares sold short, which is 1.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.54 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Interactive Brokers Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738354512_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Interactive Brokers Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Interactive Brokers Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Interactive Brokers Gr's peer group average for short interest as a percentage of float is 3.34%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

IBKR

(IBKR) - Analyzing Interactive Brokers Gr's Short Interest

U.S. equity indices reversed earlier gains and fell into negative territory during Friday afternoon trading in New York after the White House confirmed that new tariffs on imports from Canada, Mexico, and China would take effect on Saturday, escalating trade tensions with the <a href="https://www.benzinga.com/news/global/25/01/43401971/white-house-confirms-tariffs-on-key-us-trade-partners-this-weekend">country's three largest suppliers.</a>
The S&amp;P 500—tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)—fell 1%, sliding from 6,120 points at midday to 6,045 points by 2:45 p.m. ET.
The Dow Jones Industrial Average dropped 0.8% to 44,530 points, while the Nasdaq 100—tracked by the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)—fell 1.5%, reversing an earlier 1.3% gain.
Sector-wise, the Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) deepened its losses, sliding 2.9%. Meanwhile, the Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) was the only sector still in positive territory, up 0.3%, though it had pared earlier gains.
The Biden administration is imposing a 25% tariff on goods from Canada and Mexico, along with a 10% duty on Chinese imports. White House Press Secretary Karoline Leavitt stated that the measure responds to these nations&#8217; alleged role in allowing illegal fentanyl to enter the U.S.
A <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43398182/trumps-25-tariffs-could-slaughter-canada-mexico-economies-hit-us-auto-industry-analysts-warn">Goldman Sachs research note</a> published Friday estimated that GDP in Canada and Mexico could decline by 1% to 4%, with consumer prices rising up to 2% due to increased import costs.
For the U.S., the new tariffs would raise the overall tariff rate by 7.3 percentage points, resulting in a 0.7% increase in core personal consumption expenditures prices, the Federal Reserve's preferred inflation gauge, and a 0.4% drag on U.S. GDP growth.
<h3 class="wp-block-heading">Dollar Reigns Supreme, Canadian Dollar Nears 9-Year Lows</h3>
In currency markets, the U.S. dollar strengthened against all major counterparts, particularly against those most affected by the tariff announcement.
The greenback surged past 1.4520 against the Canadian dollar, on track to close the session at its highest level since January 2016.
The dollar erased earlier losses against the Mexican peso and gained 0.3% against the Chinese yuan.
A broader measure of dollar strength, as broadly followed by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), was up 0.3%.
<h3 class="wp-block-heading">Bond Yields Surge, Gold Retreats, Bitcoin Slumps</h3>
Treasury yields spiked, reflecting investor concerns over the inflationary impact of tariffs. Both 10-year Treasury yields and 30-year yields were up 5 basis points to 4.57% and 4.81%, respectively. 
As a reaction, the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 0.7%
Gold pared earlier gains amid a stronger dollar and rising yields.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) bore the brunt of the risk-off move, tumbling over 3% from $105,000 to $102,000.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43399315/apples-better-than-feared-guidance-calms-iphone-ai-china-concerns-7-analyst-reactions">Apple&#8217;s &#8216;Better Than Feared&#8217; Guidance Calms iPhone, AI, China Concerns: 7 Analyst Reactions</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Government

Macro Economic Events

Regulations

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Commodities

Currency ETFs

Econ #s

Economics

ETFs

$BTC

iShares Trust Barclays 20+ Year Treasury Bond Fund

PowerShares DB US Dollar Index Bullish Fund

Wall Street Sinks On Trump's Tariff Announcement, Bitcoin Drops 3%, Dollar Soars

BABA

BEKE

BIDU

BILI

FUTU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

TCOM

XPEV

Shares of US-listed Chinese stocks are trading lower ahead of Trump's Feb. 1 tariff deadline.

AROC

FANG

TRGP

Shares of oil and gas companies are trading lower as investors evaluate the February 1st tariff deadline for Mexico, Canada and China.

The XOVR ETF by&nbsp;ERShares, the only exchange-traded fund providing exposure to private equity, has further strengthened its position in SpaceX, the fund's largest holding.&nbsp;The&nbsp;fund increased its investment by $13 million, bringing SpaceX's total allocation to 11% of AUM.
XOVR ETF is uniquely designed to invest in entrepreneurial U.S. large-cap companies, leveraging the ER30TR Index (Entrepreneur Total Return Index), which is based on&nbsp;ERShares' Proprietary Venture Capital Model. The model&nbsp;was&nbsp;developed over the past 20 years by Dr. Joel Shulman, CEO/CIO of&nbsp;ERShares. Dr. Shulman, an early identifier of today's Magnificent 7, is now focused on uncovering the next generation of disruptive companies, sometimes investing pre-IPO.

XOVR

XOVR ETF Increases Its Investment By $13M, Bringing SpaceX's Total Allocation To 11% Of AUM

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cyclerion Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cycn-stock-quote/">CYCN</a>) just reported results for the fourth quarter of 2023.<ul><li>Cyclerion Therapeutics reported earnings per share of -$1.60.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/cycn-stock-earnings-cyclerion-therapeutics-for-q4-of-2023/">CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cyclerion Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cycn-stock-quote/">CYCN</a>) just reported results for the first quarter of 2024.<ul><li>Cyclerion Therapeutics reported earnings per share of -62 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/cycn-stock-earnings-cyclerion-therapeutics-for-q1-of-2024/">CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!



Moving stocks are a bankruptcy filing, regulator approval, a public offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Spectaire (NASDAQ:<a href="https://investorplace.com/stock-quotes/spec-stock-quote/">SPEC</a>) stock is rocketing more than 111% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318405643&amp;type=PDF&amp;symbol=SPEC&amp;cdn=402f87b97cb330efbad1632693edb216&amp;companyName=Spectaire+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-20">letter, settlement and asset purchase agreements</a>.</li>



<li>Trinity Place (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tphs-stock-quote/">TPHS</a>) shares are soaring over 52% with heavy pre-market trading today.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) stock is surging more than 45% <a href="https://finance.yahoo.com/news/dermtech-files-voluntary-chapter-11-120500056.html">despite a recent bankruptcy filing</a>.</li>



<li>Sarepta Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/srpt-stock-quote/">SRPT</a>) shares are gaining over 37% on <a href="https://www.marketwatch.com/story/sarepta-shares-soar-37-following-expanded-approval-for-elevidys-991d6de5?mod=home-page">expanded regulator approval</a>.</li>



<li>Kintara Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktra-stock-quote/">KTRA</a>) stock is increasing 27% with strong early morning trading.</li>



<li>Qualigen Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/qlgn-stock-quote/">QLGN</a>) shares are rising more than 16% with heavy trading today.</li>



<li>Unusual Machines (NYSEMKT:<a href="https://investorplace.com/stock-quotes/umac-stock-quote/">UMAC</a>) stock is climbing close to 16% despite a lack of news today.</li>



<li>Simpple (NASDAQ:<a href="https://investorplace.com/stock-quotes/sppl-stock-quote/">SPPL</a>) shares are jumping nearly 15% without any clear news today.</li>



<li>Lion Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/lghl-stock-quote/">LGHL</a>) stock is heading over 13% higher on Friday morning.</li>



<li>Solid Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/sldb-stock-quote/">SLDB</a>) shares are up more than 13% without any news to report.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Abacus Life (NASDAQ:<a href="https://investorplace.com/stock-quotes/abl-stock-quote/">ABL</a>) stock is diving over 23% after <a href="https://www.nasdaq.com/press-release/abacus-life-announces-pricing-public-offering-common-stock-2024-06-20">pricing a public offering</a>.</li>



<li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) shares are tumbling 20% on Friday morning.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) stock is taking a more than 18% beating with strong early morning trading.</li>



<li>Kaival Brands Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/">KAVL</a>) shares are sliding over 17% on Friday morning.</li>



<li>QXO (NASDAQ:<a href="https://investorplace.com/stock-quotes/qxo-stock-quote/">QXO</a>) stock is dropping 16% today.</li>



<li>Reliance Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) shares are falling more than 15% <a href="https://investorplace.com/2024/06/why-is-reliance-global-reli-stock-up-283-today/">after a recent rally</a>.</li>



<li>MGO Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgol-stock-quote/">MGOL</a>) stock is retreating over 14% <a href="https://investorplace.com/2024/06/why-is-mgo-global-mgol-stock-up-133-today/">following a rally yesterday</a>.</li>



<li>Cyclerion Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cycn-stock-quote/">CYCN</a>) shares are decreasing 14% this morning.</li>



<li>Perfect (NYSE:<a href="https://investorplace.com/stock-quotes/perf-stock-quote/">PERF</a>) stock is slipping more than 12% today.</li>



<li>Scinai Immunotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/scni-stock-quote/">SCNI</a>) shares close out our pre-market stock movers down over 11% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-june-21st/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The latest announcement is out from Cyclerion Therapeutics (CYCN). Regina Graul, Ph.D., has been promoted to Chief Executive Officer, as announced ...

Cyclerion Therapeutics Appoints New CEO Regina Graul

Cyclerion Therapeutics names Regina Graul as CEO

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Cyclerion Therapeutics (CYCN) announced an update on its progress in catalyzing the Company's next stage of growth. The Company is leveraging its l...

Cyclerion Therapeutics announces update on next stage of growth

Cyclerion Therapeutics ( ($CYCN) ) has provided an announcement. Cyclerion Therapeutics has renegotiated its praliciguat license agreement with Ake...

Comments

Cyclerion Therapeutics

뉴스

에 대한 최신 뉴스 Cyclerion Therapeutics (NASDAQ:CYCN) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌